Navigation Links
Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Date:12/13/2011

NEW YORK, Dec. 13, 2011 /PRNewswire/ -- Synergy Pharmaceuticals, Inc. (Nasdaq: SGYPD, SGYPU), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has filed a lawsuit in New York State Supreme Court against Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie. 

The lawsuit alleges that after European patent 1,379,224 was granted to Synergy but prior to issuance, Ironwood and Dr. Currie opposed the patent before the European Patent Office and presented to the European Patent Office and the United States Patent and Trademark Office, data and arguments that were false, contradictory, inaccurate and misleading.  In its complaint, Synergy accuses Ironwood and Dr. Currie of, among other things, unfair competition, fraud and unjust enrichment and seeks $500 million in actual and punitive damages.

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in patients to treat chronic idiopathic constipation (CIC) patients. In October 2011, Synergy initiated dosing of patients in a major Phase II/III clinical trial of plecanatide in CIC patients. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome, with the first trial in IBS-C patients planned for 2012. Synergy's second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel disease
'/>"/>

SOURCE Synergy Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc.
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
6. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
7. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
10. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 Whitehouse Laboratories has formally ... Stability Testing and Package Test Capacity. Responding to growing ... a dramatic increase in environmental chamber storage space that ... and aging samples to be securely held on site ... capital expenditure has already taken place with the recent ...
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... 8:30 a.m. ET in Boston, MA. ... available on the "Investors & Media" section of the Company,s ... the Isis website within 48 hours and will be archived ...
(Date:10/30/2014)... of the key challenges in the development of quantum ... , In a paper published today (28 October) in ... show how to make a new type of flexibly ... such as high-precision sensors and specialised superfast computers, often ... the methods for trapping these tiny particles are hugely ...
(Date:10/27/2014)... The new research report, “Gas ... Medium), Sub-type (Primary & Secondary), and End-User (Transmission ... & Power Generation) - Trends and Forecasts to ... analysis and forecasting of the market size. , ... 52 Figures spread through 146 Pages and in-depth ...
Breaking Biology Technology:Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... AMSTERDAM, October 13 Amsterdam Molecular,Therapeutics ... gene therapy,announced today that the European Medicines Agency has ... for the treatment of,Duchenne muscular dystrophy. , ... (DMD) entitles,AMT to ten year market exclusivity in Europe ...
... HAIKOU CITY, China, Oct. 12 ... CPHI ), which develops,manufactures, and markets specialty pharmaceutical ... the Roth China Conference, to be held,October 12-14, 2009, ... participate in one-on-one meetings with conference attendees throughout,the three-day ...
... 12 Dr. Michael Merzenich , PhD ... brain plasticity expert and tech entrepreneur - was ... Washington, D.C. Also a member of the National Academy of ... scientists and doctors in the U.S. who have been selected ...
Cached Biology Technology:AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 2AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 3Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research 2Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research 3
(Date:10/30/2014)... UT Arlington bioengineering professor has received a $1.04 ... to regenerate cartilage tissue and reduce osteoarthritis using ... injection of microscaffolding made of biodegradable polymers., Liping ... the bioengineering department, said the research is primarily ... on the battlefield., "We,ve found that if we ...
(Date:10/30/2014)... Philadelphia, PA, October 30, 2014 – Bacteria in ... are critical for digestion. Yet, these same bacteria ... system if they penetrate the gut and enter ... natural response to protect the body, chronic or ... diseases. Prior research has established the involvement of ...
(Date:10/29/2014)... by unconventional oil and gas production are well over ... the open access journal Environmental Health . High ... The study is the first to be based on ... and could be used to supplement official air-quality monitoring ... that do not readily flow to the surface. This ...
Breaking Biology News(10 mins):UTA researcher uses microscaffolding injections to mend cartilage, prevent osteoarthritis 2Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3
... Chicago, IllinoisJune 22, 2010"Seasick: Ocean Change and the ... in the US by the University of Chicago Press, ... in Environmental Reporting. Awarded by the Metcalf Institute for ... of the environment and recognizes reporting that has the ...
... puzzled over why a baby,s brain is particularly flexible ... have to learn a lot? A group of researchers ... Institute for Dynamics and Self-Organization in Gttingen, the Schiller ... put forward a new explanation: Maybe it is because ...
... (June 20, 2010) By emulating nature,s design principles, ... Engineering, Harvard Medical School and Dana-Farber Cancer Institute has ... be programmed to move and change shape on demand. ... highly suitable for medical applications because DNA is both ...
Cached Biology News:Growing brain is particularly flexible 2Researchers create self-assembling nanodevices that move and change shape on demand 2
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Mouse polyclonal antibody raised against a partial recombinant CD320. NCBI Entrez Gene ID = 51293...
Mouse monoclonal antibody raised against a partial recombinant CHD8. NCBI Entrez Gene ID = CHD8...
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Biology Products: